China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Want to cut your energy bills? Here’s how five experts are doing it 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SAN DIEGO, May 25, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for its two most advanced clinical stage oncology product candidates, TRC105 and TRC102, at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held June 2-6, 2017, in Chicago, Illinois.
The following is a summary of the four presentations that will be given at ASCO:
| Poster Discussion Presentations | |
| Title: | A Phase I Trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients |
| with solid tumors and lymphomas (Abstract #2518) | |
| Presenter: | Robert S. Meehan, MD, National Cancer Institute |
| Location: | S Hall A, Poster Board 10 (poster display) |
| Arie Crown Theater (poster discussion) | |
| Date/Time: | Monday, June 5, 2017, 8:00 AM – 11:30 AM, Central time (poster display) |
| Monday, June 5, 2017, 11:30 AM – 12:45 PM, Central time (poster discussion) | |
| Title: | NCCTG N1174: Phase I/comparative randomized Phase II trial of TRC105 plus |
| bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Abstract #2023) | |
| Presenter: | Evanthia Galanis, MD, Mayo Clinic |
| Location: | S Hall A, Poster Board 265 (poster display) |
| S404 (poster discussion) | |
| Date/Time: | Monday, June 5, 2017, 1:15 PM – 4:45 PM, Central time (poster display) |
| Monday, June 5, 2017, 4:45 PM – 6:00 PM, Central time (poster discussion) | |
| General Poster Presentations | |
| Title: | Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF |
| therapy (Abstract #11546) | |
| Presenter: | Yingmiao Liu, Ph.D., Duke University Medical Center |
| Location: | S Hall A, Poster Board 246 |
| Date/Time: | Saturday, June 3, 2017, 1:15 PM – 4:45 PM, Central time |
| Title: | TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus |
| pazopanib alone in patients with advanced angiosarcoma (Abstract #TPS11081) | |
| Presenter: | Robin Lewis Jones, BSc, MB, MRCP, MD, Royal Marsden Hospital |
| Location: | S Hall A, Poster Board 403a |
| Date/Time: | Sunday, June 4, 2017, 8:00 AM – 11:30 AM, Central time |
About Carotuximab (TRC105)
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 and multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumors in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.
About TRC102
TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
